Core Insights - Precipio, Inc. is set to present findings from a joint study with Memorial Sloan Kettering Cancer Center, highlighting the positive impacts of its BCR::ABL1 assay on patient care [1][2] Group 1: Study Findings - The comprehensive study involved 895 patient samples and demonstrated superior performance of the BCR::ABL1 assay, showing concordance with two other leading platforms [2] - The study indicates clear, positive impacts on patient care and significant improvements in laboratory workflows [2] Group 2: Company Overview - Precipio is a healthcare biotechnology company focused on cancer diagnostics, aiming to address cancer misdiagnoses through innovative diagnostic products and services [3] - The company's mission includes delivering higher accuracy and improved laboratory workflow, ultimately leading to better patient outcomes and reduced healthcare expenses [3]